NCT03322631View on ClinicalTrials.gov

A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

May 29, 2018

Study Completion Date

November 28, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Tirzepatide

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (2)

192-0071

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Hachiōji

169-0073

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03322631 - A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter